BIM 23B065

Drug Profile

BIM 23B065

Alternative Names: BIM23B065

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ipsen
  • Class
  • Mechanism of Action Dopamine D2 receptor agonists; Somatostatin receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Acromegaly
  • Phase I Pituitary ACTH hypersecretion

Most Recent Events

  • 02 Jun 2017 Ipsen terminates a phase II trial in Acromegaly (In the elderly, In adults) in Belarus, Belgium, Bulgaria, Hungary, Serbia and Ukraine (NCT03045302)
  • 06 Oct 2016 Phase-II clinical trials in Acromegaly (In the elderly, In adults) in Hungary (SC) in October 2016 (EUDRACT2015-003868-37)
  • 01 Jan 2016 Phase-I clinical trials in Pituitary ACTH Hypersecretion in USA (SC) before January 2016 (Ipsen pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top